CoChat

Management recommendations for pancreatic manifestations of von Hippel–Lindau disease

Laks, Shachar, van Leeuwaarde, Rachel, Patel, Dhaval, Keutgen, Xavier M., Hammel, Pascal, Nilubol, Naris, Links, Thera P., Halfdanarson, Thorvardur R., Daniels, Anthony B., Tirosh, Amit, for the Pancreatic Manifestations Recommendations Development Subcommittee of the VHL Alliance · 2022 · Cancer
Cited by 51

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Von Hippel–Lindau disease (VHL) is a multineoplasm inherited disease manifesting with hemangioblastoma of the central nervous system and retina, adrenal pheochromocytoma, renal cell carcinoma, pancreatic neuroendocrine tumors and cysts, and neoplasms/cysts of the ear, broad ligament, and testicles. During 2018‐2020, the VHL Alliance gathered several committees of experts in the various clinical manifestations of VHL to review the literature, gather the available evidence on VHL, and develop recommendations for patient management. The current report details the results of the discussion of a group of experts in the pancreatic manifestations of VHL along with their proposed recommendations for the clinical surveillance and management of patients with VHL. The recommendations subcommittee performed a comprehensive systematic review of the literature and conducted panel discussions to reach the current recommendations. The level of evidence was defined according to the Shekelle variation of the Grading of Recommendations, Assessment, Development, and Evaluation grading system. The National Comprehensive Cancer Network Categories of Evidence and Consensus defined the committee members' interpretation of the evidence and degree of consensus. The recommendations encompass the main aspects of VHL‐related pancreatic manifestations and their clinical management. They are presented in a clinical orientation, including general planning of screening and surveillance for pancreatic neuroendocrine tumors, utility of biochemical biomarkers, the optimal choice for imaging modality, indirect risk stratification, indications for tissue sampling of VHL‐related pancreatic neuroendocrine tumors, and interventions. These recommendations are designed to serve as the reference for all aspects of the screening, surveillance, and management of VHL‐related pancreatic manifestations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.33978

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 79

  1. 10.1136/jmg.28.7.443 · DOI · Paper page
  2. 10.1016/0140-6736(91)91705-Y · DOI · Paper page
  3. 10.1126/science.8493574 · DOI · Paper page
  4. 10.1016/S0140-6736(03)13643-4 · DOI · Paper page
  5. 10.1677/ERC-10-0037 · DOI
  6. 10.1053/gast.2000.18143 · DOI · Paper page
  7. 10.1007/s00535-013-0794-1 · doi:10.1007/s00535-013-0794-1
  8. 10.1016/j.surg.2007.09.012 · doi:10.1016/j.surg.2007.09.012
  9. 10.1530/ERC-18-0100 · DOI
  10. 10.1159/000457956 · DOI · Paper page
  11. 10.1159/000443172 · DOI · Paper page
  12. 10.1001/jamaoncol.2017.3428 · DOI
  13. 10.1038/nrclinonc.2016.37 · DOI
  14. 10.1159/000443171 · DOI · Paper page
  15. 10.1097/MPA.0000000000001597 · DOI · Paper page
  16. 10.1136/bmj.318.7183.593 · DOI · Paper page
  17. NCCN Categories of Evidence and Consensus and NCCN Categories of Preference
  18. 10.1007/s10689-019-00131-x · DOI
  19. 10.1530/ERC-13-0308 · DOI
  20. 2021, Clinical care centers
  21. 10.1038/ejhg.2016.173 · DOI
  22. 10.1212/WNL.0000000000002064 · doi:10.1212/wnl.0000000000002064
  23. 10.1159/000472254 · DOI · Paper page
  24. 10.1016/j.jamcollsurg.2013.10.025 · DOI
  25. 10.1245/s10434-010-1006-3 · DOI · Paper page
  26. 10.1530/ERC-17-0269 · DOI · Paper page
  27. 10.1530/EJE-16-1079 · DOI
  28. 10.21037/jtd.2017.03.82 · DOI
  29. 10.1530/EC-20-0417 · DOI
  30. Al‐Toubah T, 2020, Sensitivity and specificity of the NETest: a validation study, Neuroendocrinology
  31. 10.1245/s10434-020-08464-z · doi:10.1245/s10434-020-08464-z
  32. 10.1159/000471879 · DOI · Paper page
  33. 10.1148/radiol.2253011297 · doi:10.1148/radiol.2253011297
  34. 10.1016/j.ejrad.2018.11.023 · doi:10.1016/j.ejrad.2018.11.023
  35. 10.1016/j.surg.2011.09.048 · DOI
  36. 10.1016/j.ejso.2007.07.209 · DOI
  37. 10.1530/EJE-15-1012 · doi:10.1530/eje-15-1012
  38. 10.3748/wjg.v18.i34.4659 · doi:10.3748/wjg.v18.i34.4659
  39. 10.1148/radiol.2018180687 · DOI
  40. 10.1016/j.jamcollsurg.2014.01.004 · DOI
  41. 10.1097/RLU.0000000000001315 · DOI
  42. 10.1097/RLU.0000000000001314 · DOI
  43. 10.1097/RLU.0000000000001393 · DOI
  44. 10.1097/RLU.0000000000001511 · DOI
  45. 10.1038/srep40822 · DOI
  46. 10.1007/s00259-016-3421-6 · DOI
  47. 10.1016/j.surg.2012.08.010 · doi:10.1016/j.surg.2012.08.010
  48. 10.12998/wjcc.v7.i23.4119 · doi:10.12998/wjcc.v7.i23.4119
  49. 10.1210/clinem/dgz314 · DOI
  50. 10.1097/SLA.0000000000000856 · DOI
  51. 10.1210/jc.2017-02434 · DOI
  52. 10.1186/s12893-020-01004-2 · DOI
  53. 10.1097/MPA.0000000000001454 · DOI · Paper page
  54. 10.1067/msy.2000.110239 · DOI
  55. 10.3748/wjg.v16.i36.4515 · doi:10.3748/wjg.v16.i36.4515
  56. 10.1097/MPA.0000000000000133 · DOI
  57. 10.4240/wjgs.v7.i4.52 · DOI · Paper page
  58. 10.1055/a-0824-7067 · DOI
  59. 10.1210/jc.2019-00282 · DOI
  60. 10.1016/j.ejso.2003.10.013 · doi:10.1016/j.ejso.2003.10.013
  61. 10.1159/000443167 · DOI · Paper page
  62. 10.1002/cncr.31930 · DOI
  63. 10.3389/fonc.2019.01122 · DOI
  64. 10.1056/NEJMoa1003825 · DOI · Paper page
  65. 10.1097/MCG.0000000000000160 · DOI
  66. 10.1080/15384047.2018.1470732 · DOI
  67. 10.1210/jc.2008-1972 · DOI
  68. 10.1097/MPA.0b013e31822a645e · DOI
  69. 10.1016/S1470-2045(18)30487-X · DOI · Paper page
  70. 10.18632/oncotarget.4564 · DOI
  71. 2021, FDA approves belzutifan for cancers associated with von Hippel–Lindau disease
  72. 10.1007/s11605-012-1847-0 · DOI
  73. 10.1001/archinte.1976.03630070017007 · doi:10.1001/archinte.1976.03630070017007
  74. 10.1097/MPA.0000000000000875 · DOI
  75. Medina D, 2014, Biliary and gastric drainage in advanced pancreatic serous cystadenoma and portal hypertension in von Hippel–Lindau syndrome, J Gastrointest Oncol, 5, E50
  76. 10.1007/s002689900234 · doi:10.1007/s002689900234
  77. Boujaoude J, 2007, A benign cause of obstructive jaundice with von Hippel–Lindau disease. A case report and review of the literature, JOP, 8, 790
  78. Deboever G, 1992, Common bile duct obstruction due to pancreatic involvement in the von Hippel–Lindau syndrome, Am J Gastroenterol, 87, 1866
  79. 10.1016/j.gcb.2008.01.041 · doi:10.1016/j.gcb.2008.01.041

Metadata

Authors
Laks, S., van Leeuwaarde, R., Patel, D., Keutgen, X. M., Hammel, P., Nilubol, N., Links, T. P., Halfdanarson, T. R., Daniels, A. B., Tirosh, A., & for the Pancreatic Manifestations Recommendations Development Subcommittee of the VHL Alliance
Venue
Cancer
Publisher
Wiley
Published
2021-11-04
Volume
128
Issue
3
Pages
435-446
ISSN
  • 0008-543X
  • 1097-0142
Cited by
51
References
4
Language
en
Funders
National Eye Institute (5K08EY027464‐02)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management recommendations for pancreatic manifestations of von Hippel–Lindau disease. https://app.cochat.ai/papers/10.1002/cncr.33978
The paper
Laks, S., van Leeuwaarde, R., Patel, D., Keutgen, X. M., Hammel, P., Nilubol, N., Links, T. P., Halfdanarson, T. R., Daniels, A. B., Tirosh, A., & for the Pancreatic Manifestations Recommendations Development Subcommittee of the VHL Alliance. (2022). Management recommendations for pancreatic manifestations of von Hippel–Lindau disease. Cancer. https://doi.org/10.1002/cncr.33978

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.